Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant [177Lu]Lu-PSMAI&T radioligand therapy followed by radical prostatectomy in oligometastatic prostate cancer
2024-519377-18-00Phase 2Authorised
- Sponsor
- Medical University of Vienna
- Start
- Jan 2025
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of lutetium (177lu) psma i&t in prostate cancer (PCa), sponsored by Medical University of Vienna. Primary endpoint: Safety and toxicity of neoadjuvant PSMA-RLT and radical prostatectomy. Planned start Jan 2025; status: authorised.
02
Drugs
lutetium (177lu) psma i&t
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on 2024-519377-18-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-519377-18-00.